Last reviewed · How we verify
Pegylated Interferon and Imatinib
This combination uses pegylated interferon to enhance immune response against cancer cells while imatinib inhibits tyrosine kinases to block tumor cell proliferation and survival signaling.
This combination uses pegylated interferon to enhance immune response against cancer cells while imatinib inhibits tyrosine kinases to block tumor cell proliferation and survival signaling. Used for Chronic myeloid leukemia (CML) in phase 3 development.
At a glance
| Generic name | Pegylated Interferon and Imatinib |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | Combination therapy: interferon alpha (immunomodulator) + tyrosine kinase inhibitor |
| Target | Interferon-alpha receptor; BCR-ABL, KIT, PDGFR (imatinib targets) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pegylated interferon-alpha activates innate and adaptive immune responses, enhancing natural killer cell and T-cell activity against malignant cells. Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases, preventing tumor cell growth and inducing apoptosis. The combination aims to synergize immunological and targeted mechanisms.
Approved indications
- Chronic myeloid leukemia (CML) in phase 3 development
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Myelosuppression (neutropenia, thrombocytopenia)
- Gastrointestinal toxicity (nausea, diarrhea)
- Hepatotoxicity
- Depression/neuropsychiatric effects
Key clinical trials
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PHASE2)
- Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia (PHASE2)
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia (PHASE2)
- Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy (PHASE3)
- Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Interferon and Imatinib CI brief — competitive landscape report
- Pegylated Interferon and Imatinib updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI